Filing Flows › Artivion (AORT) › Q2 2026 › vs Q2 2025
Artivion (AORT) Q2 2026 vs Q2 2025 (year over year)
Artivion's revenue rose $12.8M (+11%) from $113M in Q2 2025 to $126M in Q2 2026. The biggest changes: Products +$12.5M (+14%); Preservation services +$324K (+1%).
Artivion, Q2 2026: revenue $126M (+11% year over year), operating margin -6.7%, net loss $13.5M, operating cash flow −$1.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Aortic stent grafts | $46.4M | $39.8M | $6.6M | +16% |
| On-X | $30.5M | $25.6M | $4.9M | +19% |
| Surgical sealants | $19.3M | $19.3M | −$1K | 0% |
| Other | $3.7M | $2.7M | $955K | +35% |
| Products | $99.9M | $87.4M | $12.5M | +14% |
| Preservation services | $25.9M | $25.5M | $324K | +1% |
| Revenue | $126M | $113M | $12.8M | +11% |
| Net loss | $13.5M | −$1.3M | $14.9M | — |
| Costs & expenses | $139M | $113M | $26.3M | +23% |
| Operating costs | $134M | $105M | $29.5M | +28% |
| Interest & other, net | $3.3M | $4.9M | −$1.6M | -32% |
| Income tax | $1.8M | $2.1M | −$326K | -15% |
| Cost of revenue | $45.2M | $39.9M | $5.4M | +13% |
| Research & development | $9.1M | $7.1M | $2.0M | +28% |
| SG&A | $79.8M | $57.7M | $22.2M | +38% |
| Operating cash sources | $16.2M | −$3.4M | $19.5M | — |
| Depreciation & amortization | $6.7M | $5.5M | $1.2M | +22% |
| Share-based compensation | $8.2M | $6.1M | $2.0M | +33% |
| Cash used in operations | $1.3M | −$15.0M | $16.3M | — |
| Net loss absorbed | $13.5M | −$1.3M | $14.9M | — |
| Working capital & other | $2.7M | −$2.0M | $4.7M | — |
Questions
How much did Artivion's revenue grow year over year in Q2 2026?
Artivion's revenue rose $12.8M (+11%) from $113M in Q2 2025 to $126M in Q2 2026.
What drove Artivion's revenue change in Q2 2026?
Products +$12.5M (+14%); Preservation services +$324K (+1%).